ArticleBiomedicines2021

Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway.

Shin-Yi Chung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.